Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin in HER2-high advanced or metastatic extramammary Paget's disease
ChiCTR2500100703Phase 2Completed
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- May 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in extramammary Paget disease (EMPD), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: objective response rate. Started May 2024; status: completed.
02
Drugs
disitamab vedotin
03
Conditions
extramammary Paget disease (EMPD)
Beyond the preview
Go deeper on ChiCTR2500100703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100703.